AGX101
Now treating patients in a Phase 1 Clinical Trial

AGX101 is a TM4SF1-directed antibody and microtubule inhibitor conjugate

Our lead product is a first-in-class ADC

Our lead drug, AGX101, is the first Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC).

Preclinically, AGX101 has demonstrated a wide therapeutic window – there are no adverse clinical signs in animals at efficacious doses. Prior clinical studies with a TM4SF1-directed radioimmunoconjugate demonstrated clinically significant responses in 60% of patients with negligible vascular toxicity.

Due to TM4SF1’s widespread expression in tumor cells and tumor vasculature, AGX101 has potential to treat most solid cancers. In many cancers, high TM4SF1 expression is associated with early death, suggesting that killing of high-TM4SF1 cancer cells by AGX101 may convert cancers to a less malignant form.

TM4SF1 is highly expressed during embryonic development but has low expression in all normal tissues of adults, supporting the potential for AGX101 to have a wide therapeutic margin.

In Phase 1, AGX101 will treat patients with unresectable, locally advanced, or metastatic solid tumors.

Download poster

Nuclear Delivery Platform™

Angiex’s Nuclear Delivery Platform™ consists of proprietary TM4SF1-directed antibodies, site-specific conjugation method, and linkers.

A wide range of drug payloads, including traditional chemotherapies and targeted small molecules as well as newer modalities like protein degraders and RNA, can be conjugated to make Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs).

Efficacy

ND-ADCs give their drug payloads direct access to nuclear and cytosolic targets, enhancing efficacy and eliminating some resistance mechanisms.

Safety

ND-ADCs deliver their drug payloads only to TM4SF1 expressing cells. This eliminates many common cancer therapy side effects, such as neutropenia, thrombocytopenia, and digestive tract distress.

Potential

With ND-ADC delivery, drug payloads can be designed solely for their therapeutic activity and pharmacodynamic properties; they do not need to be “drug-like”. This enables new chemistries and treatment of “undruggable” targets.

Preclinical pipeline

In discovery-stage development, Angiex has created a diverse portfolio of pipeline ND-ADCs using small molecule and protein degrader payloads. Payloads include traditional cytotoxic chemotherapies and targeted cancer therapies.

AGX101Now treating patients in a Phase 1 Clinical Trial